Trials / Completed
CompletedNCT03489733
Prevention of Allergic Diseases in Infants
The Effect of Low Protein, Extensively Hydrolyzed Infant Formula on Allergy Prevention in At-risk Infants up to 1 Year of Age: a Randomized, Double-blind, Controlled Intervention Study and the Long-term Effect on Allergy Prevention of Early Nutrition Given in the First 120 Days of Life in At-risk Infants Until the Child is 6 Years of Age
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,226 (actual)
- Sponsor
- HiPP GmbH & Co. Vertrieb KG · Industry
- Sex
- All
- Age
- 56 Days
- Healthy volunteers
- Accepted
Summary
A multi-center, prospective, randomized, controlled, doubleblind intervention clinical Trial is performed to proof the efficiency of hydrolyzed infant formula showing a risk reduction of developing an allergy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Hydrolyzed Formula | Infant formula with extensively hydrolyzed proteins and pre- and probiotics. |
| OTHER | Control formula | Infant formula with intact proteins and pre- and probiotics. |
Timeline
- Start date
- 2018-07-09
- Primary completion
- 2021-03-31
- Completion
- 2025-10-30
- First posted
- 2018-04-05
- Last updated
- 2026-03-09
Locations
14 sites across 10 countries: Bulgaria, Czechia, Finland, France, Germany, Italy, Poland, Portugal, Serbia, Spain
Source: ClinicalTrials.gov record NCT03489733. Inclusion in this directory is not an endorsement.